Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
McKesson
Medtronic
Mallinckrodt
Healthtrust
Harvard Business School
Johnson and Johnson
Fish and Richardson
US Department of Justice
Express Scripts

Generated: December 11, 2017

DrugPatentWatch Database Preview

Eli Lilly Co Company Profile

« Back to Dashboard

What is the competitive landscape for ELI LILLY CO, and when can generic versions of ELI LILLY CO drugs launch?

ELI LILLY CO has two approved drugs.

There are four US patents protecting ELI LILLY CO drugs.

There are two hundred and seventy-nine patent family members on ELI LILLY CO drugs in fifty-four countries and sixteen supplementary protection certificates in ten countries.

Summary for Eli Lilly Co

International Patents:279
US Patents:4
Tradenames:2
Ingredients:2
NDAs:2
Drug Master File Entries: 1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Eli Lilly CoZYPREXA RELPREVVolanzapine pamoateSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-001Dec 11, 2009RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Eli Lilly CoADCIRCAtadalafilTABLET;ORAL022332-001May 22, 2009RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Eli Lilly CoZYPREXA RELPREVVolanzapine pamoateSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-003Dec 11, 2009RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Eli Lilly CoADCIRCAtadalafilTABLET;ORAL022332-001May 22, 2009RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Eli Lilly CoZYPREXA RELPREVVolanzapine pamoateSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-002Dec 11, 2009RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Eli Lilly CoADCIRCAtadalafilTABLET;ORAL022332-001May 22, 2009RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Eli Lilly Co

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly CoZYPREXA RELPREVVolanzapine pamoateSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-001Dec 11, 2009► Subscribe► Subscribe
Eli Lilly CoADCIRCAtadalafilTABLET;ORAL022332-001May 22, 2009► Subscribe► Subscribe
Eli Lilly CoZYPREXA RELPREVVolanzapine pamoateSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-003Dec 11, 2009► Subscribe► Subscribe
Eli Lilly CoZYPREXA RELPREVVolanzapine pamoateSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-002Dec 11, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ELI LILLY CO drugs

Drugname Dosage Strength Tradename Submissiondate
tadalafilTablets20 mgADCIRCA10/15/2009

Non-Orange Book Patents for Eli Lilly Co

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,608,065 Use of cGMP phosphodiesterase inhibitors in methods to treat female sexual dysfunction► Subscribe
5,981,527 Cyclic GMP-specific phosphodiesterase inhibitors► Subscribe
6,784,179 Tetracyclic derivatives, process of preparation and use► Subscribe
6,617,321 2-methyl-thieno-benzodiazepine formulation► Subscribe
6,369,059 Tetracyclic derivatives, process of preparation and use► Subscribe
6,140,329 Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence► Subscribe
7,303,7642-methyl-thieno-benzodiazepine formulation► Subscribe
6,143,746 Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use► Subscribe
6,841,167 .beta.-carboline pharmaceutical compositions► Subscribe
6,127,542 Tetracyclic derivatives, process of preparation and use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Eli Lilly Co Drugs

Country Document Number Estimated Expiration
China1271251► Subscribe
Poland199469► Subscribe
Australia6508400► Subscribe
China1311828► Subscribe
Japan2002524516► Subscribe
European Patent Office2338491► Subscribe
Slovenia1468689► Subscribe
Norway20020532► Subscribe
Eurasian Patent Organization002580► Subscribe
Poland324527► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Eli Lilly Co Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
70015Netherlands► SubscribePRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927
2003 00008Denmark► Subscribe
0813Netherlands► SubscribePRODUCT NAME: AMBRISENTAN TOEGEPAST IN COMBINATIEBEHANDELING MET TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 (C(2008) 1637) 20151125
2016 00024Denmark► SubscribePRODUCT NAME: AMBRISENTAN USED IN COMBINATION TREATMENT WITH TADALAFIL; REG. NO/DATE: EU/1/08/451 (001-004) 20151125
0124Netherlands► Subscribe300124, 20150119, EXPIRES: 20171111
2016000039Germany► SubscribePRODUCT NAME: AMBRISENTAN IN VERWENDUNG IN DER KOMBINATIONSTHERAPIE MIT TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 20151120
C0017France► SubscribePRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112
017Luxembourg► Subscribe
081Luxembourg► SubscribePRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125
0740668/01Switzerland► SubscribePRODUCT NAME: TADALAFILUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56018 04.05.2004
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Merck
Harvard Business School
Mallinckrodt
Chinese Patent Office
Fuji
Argus Health
Teva
Cantor Fitzgerald
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot